Patient characteristics, treatment patterns, clinical outcomes, and health care resource utilization in severe asthma subgroups: A retrospective analysis of the International Severe Asthma Registry (EVEREST)

Study identification

• EU PAS number:
  EUPAS106967
• Study ID:
  106968
• Official title and acronym:
  Patient characteristics, treatment patterns, clinical outcomes, and health care resource utilization in severe asthma subgroups: A retrospective analysis of the International Severe Asthma Registry (EVEREST)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Australia

  Bulgaria

  Canada

  Colombia

  Denmark

  Greece

  India

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Poland

  Portugal

  Saudi Arabia

  Spain

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study description:
  Asthma is a heterogeneous disease with a complex pathophysiology that presents with a wide range of clinical manifestations and treatment responses. Recent advances in treatment strategies for severe asthma include the development and release of targeted biologics for treatment. Eligibility for biologic treatment is based on clinical and pathobiological markers, including biomarkers such as immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO), and blood eosinophil count (BEC). Despite these advances in treatment, the clinical burden for severe asthma remains high. The primary goal of this analysis is to use data from the International Severe Asthma Registry (ISAR) registry to describe characteristics and unmet needs for patients with subtypes of severe asthma, including patients who are ineligible for current biologic treatment (biologic-ineligible), patients who are biologic-eligible, patients who are biologic-eligible with and without biologic treatment, patients on biologic therapy with uncontrolled asthma, patients with multiple positive asthma-specific biomarkers, patients with low vs high blood eosinophils count (BEC), and patients with allergic asthma. As an exploratory objective, this study will also examine the variability of asthma-specific biomarkers over time.
• Study status:
  Finalised

Research institutions and networks

Institutions

Optimum Patient Care (OPC)

United Kingdom

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Study timelines

Date when funding contract was signed

Planned:05/08/2021

Actual:05/08/2021

Study start date

Planned:01/12/2017

Actual:31/05/2022

Date of final study report

Planned:31/10/2021

Actual:31/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable